Records containing: Recurrent Uterine Corpus Carcinoma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2017-08-24
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
CLINICAL_TRIALS study record update · 2017-08-23
Validating The Prognostic Role of ATR Mutation in Patients With Endometrioid Endometrial Cancer
CLINICAL_TRIALS study record update · 2016-10-28
Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
CLINICAL_TRIALS study record update · 2016-10-04
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
CLINICAL_TRIALS study record update · 2016-02-05
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2014-08-15
A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus
CLINICAL_TRIALS study record update · 2014-06-24
Phase II Study of Faslodex ? in Recurrent/Metastatic Endometrial Carcinoma
CLINICAL_TRIALS study record update · 2014-01-20
A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma